[关键词]
[摘要]
中医药的特色与优势促进了其治疗与胰岛素抵抗相关的慢性代谢性疾病如肥胖、糖尿病等的发展,但其尚不明确的作用机制极大限制了中药现代化、国际化和产业化。随着2代/3代基因测序技术的飞速发展,肠道菌群已成为中药作用机制研究的热点和新途径。为此,探讨肠道菌群及其代谢产物与胰岛素抵抗的关系,从中药复方、药对、单味药和活性成分不同角度系统分析中药通过调控肠道菌群改善胰岛素抵抗的研究进展,以期为阐释中药的作用机制提供研究思路与参考。
[Key word]
[Abstract]
The characteristics and advantages of traditional Chinese medicine (TCM) have promoted the development of TCM in the treatment of chronic metabolic diseases such as obesity and diabetes related to insulin resistance. However, the ambiguity of their corresponding mechanisms has greatly limited the modernization, internationalization and industrialization of Chinese materia medica (CMM). With the rapid development of second-/three-generation gene sequencing technologies, gut microbiota has become a hotspot and a new approach to study the mechanisms of CMM. Therefore, in this review, we explored the relationship between gut microbiota, metabolites of gut microbiota and insulin resistance, and then analyzed the research progress of CMM in regulating gut microbiota to improve insulin resistance by formulae, herb pair, single herb and active ingredients, so as to provide new thoughts for studying the mechanism of CMM.
[中图分类号]
[基金项目]
国家“重大新药创制”科技重大专项(2017ZX09301-040);国家自然科学基金青年基金项目(81903786);陕西省自然科学基金项目(2019JQ-054);陕西省高校科协青年人才托举计划项目(20190306);陕西中医药大学学科创新团队(2019-YL10)